Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Novo Nordisk hits out as Dutch agency advises against insurance cover for Wegovy

Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance

The Independent UK

Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study

Novo Nordisk stock popped Friday after a study showed its diabetes and weight-loss drug could lower the risk of developing dementia.

Investors Business Daily

Big Pharma’s Monopoly On Ozempic Threatens Access To Diabetes Drug In Communities Of Color

Small pharmacies find difficulty in prescribing the drug due to Big Pharma restrictions on the industry. ‌

Zenger

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer stock leaps on obesity drug challenge to Ozempic, Zepbound

Pfizer is looking to challenge leaders Eli Lilly and Novo Nordisk in the fast-growing market for weight loss drugs.

The Street

Nvidia Chipmaker Taiwan Semi, Arm Stock Among Best Global Stocks To Watch

Arm stock and Nvidia chipmaker Taiwan Semiconductor are among the best global stocks to buy and watch on the stock market today.

Investors Business Daily

Will Novo Nordisk's (NVO) Q2 Earnings Reflect Its Market Potential?

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….

StockNews.com

These weight-loss startups tell customers they can stop taking Ozempic or Wegovy and stay thin. Doctors disagree

As nearly $1 billion of venture capital dollars have been injected into weight-loss startups since 2023, companies are making unproven claims to attract customers. It’s a new twist on a story as old as the diet industry.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

Shares in Novo Nordisk were down 1.1% after the study

The Independent UK

Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic

Patients lost more significantly more weight on Eli Lilly's Mounjaro than Novo Nordisk's Ozempic, according to a new study.

Investors Business Daily

Eli Lilly Weight Loss Drug Beats Ozempic In Head-to-head Study

Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

International Business Times

Copper, Gold Stocks Sparkle On Rate-Cut Hopes, Among 5 Leaders Near Buy Points

Southern Copper and gold stock Agnico eagle surged above early buy points on hopeful signs for U.S. and China policy.

Investors Business Daily

Stock Market: S&P 500, Nasdaq Hit Highs As Tesla Soars, Rate-Cut Hopes Rise: Weekly Review

Tesla drove the S&P 500 and Nasdaq to highs, though small caps fell for the week. Cooling economic data raised rate-cut hopes.

Investors Business Daily

Ozempic maker slams Biden after the president accused the drug company of ‘ripping off’ US consumers

Remarks came after the president and Senator Bernie Sanders blasted the pharmaceutical giant for its ‘unconscionably high prices’

The Independent UK

Novo, Lilly Tumble After Study Ties Blindness Disorder To Weight-Loss Drugs

Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Weight-loss jabs may be linked to condition that can cause blindness, study finds

People with diabetes on semaglutide, found in Wegovy and Ozempic, four times more likely to be diagnosed with disease of optic nerve

Evening Standard

Ozempic weight loss drug linked to higher risk of eye condition that causes blindness

US study says patients could have higher risk of developing NAION

Investors Business Daily

Palantir Spearheads This Brigade Of Breakout Stocks

Palantir stock, Google stock, CrowdStrike and Netflix lead the latest IBD Breakout ETF list of breakout stocks to watch.

Investors Business Daily

Dow Jones Jumps 162 Points As Powell Says This On Rate Cuts; Tesla Value Soars $68 Billion As Deliveries Crush Views

The Dow Jones rose after Fed Chair Jerome Powell spoke out on inflation. Tesla surged on deliveries. President Biden hit out at some firms.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novo, Lilly Fall After Biden Slams Duo For 'Unconscionably High' Drug Prices

Novo Nordisk stock fell Tuesday after Joe Biden and Bernie Sanders slammed the drugmaker and Eli Lilly for high prices of weight-loss drugs.

International Business Times

Biden Calls For Lower Prices Of Ozempic, Similar Drugs

US President Joe Biden on Tuesday called on pharmaceutical giants Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs such as Ozempic, saying firms must stop "ripping off the American people."

The Street

Stock Market Today: Stocks mixed after Powell comments; Tesla leaps

Stocks are closely tracking Treasury bond yields following a solid start to the third quarter and ahead of a key labor-market reading later in the session.

Investors Business Daily

Amazon, Meta Spearhead Fresh Batch Of Breakouts As Nvidia Shows Resilience

As Nvidia tests support, Amazon breaks out and Meta moves toward a new buy point, IBD Leaderboard highlights more breakouts.

Investors Business Daily

Stock Market Rally Powers To Fresh Highs; Carnival, Micron, Nike In Focus: Weekly Review

The S&P 500 and Nasdaq hit fresh all-time highs. Software, small caps and megacaps were stock market standouts.

Barchart

1 Huge New Reason This Diet Drug Stock is a Must-Own

The recent announcement that China approved Novo Nordisk's Wegovy is huge. Here's why: In a national survey conducted during 2015-2019 by China’s National Health Commission, more than half of the adult population was either overweight or obese. That's a massive market that just opened up for NVO.

Fortune

Novo Nordisk’s Wegovy may just have two years to take over China’s market for weight loss drugs

Novo Nordisk's China patent on Wegovy's active ingredient expires in 2026, much earlier than its patents in the U.S., Japan and Europe.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations